These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32146176)

  • 41. Monoamine Oxidase Inhibitory Activity: Methyl- versus Chlorochalcone Derivatives.
    Mathew B; Uçar G; Mathew GE; Mathew S; Kalatharakkal Purapurath P; Moolayil F; Mohan S; Varghese Gupta S
    ChemMedChem; 2016 Dec; 11(24):2649-2655. PubMed ID: 27902880
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of Selected Natural Compounds as Dual Inhibitors of Catechol-O-Methyltransferase and Monoamine Oxidase.
    Engelbrecht I; Petzer JP; Petzer A
    Cent Nerv Syst Agents Med Chem; 2019; 19(2):133-145. PubMed ID: 31258092
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents.
    Carradori S; Ortuso F; Petzer A; Bagetta D; De Monte C; Secci D; De Vita D; Guglielmi P; Zengin G; Aktumsek A; Alcaro S; Petzer JP
    Eur J Med Chem; 2018 Jan; 143():1543-1552. PubMed ID: 29126727
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design, synthesis and evaluation of 2-(indolylmethylidene)-2,3-dihydro-1-benzofuran-3-one and 2-(indolyl)-4H-chromen-4-one derivatives as novel monoamine oxidases inhibitors.
    Takao K; U S; Kamauchi H; Sugita Y
    Bioorg Chem; 2019 Jun; 87():594-600. PubMed ID: 30933784
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Understanding the Molecular Determinant of Reversible Human Monoamine Oxidase B Inhibitors Containing 2H-Chromen-2-One Core: Structure-Based and Ligand-Based Derived Three-Dimensional Quantitative Structure-Activity Relationships Predictive Models.
    Mladenović M; Patsilinakos A; Pirolli A; Sabatino M; Ragno R
    J Chem Inf Model; 2017 Apr; 57(4):787-814. PubMed ID: 28291352
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potent and highly selective dual-targeting monoamine oxidase-B inhibitors: Fluorinated chalcones of morpholine versus imidazole.
    Mathew B; Baek SC; Thomas Parambi DG; Lee JP; Mathew GE; Jayanthi S; Vinod D; Rapheal C; Devikrishna V; Kondarath SS; Uddin MS; Kim H
    Arch Pharm (Weinheim); 2019 Apr; 352(4):e1800309. PubMed ID: 30663112
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potent and Selective Monoamine Oxidase-B Inhibitory Activity: Fluoro- vs. Trifluoromethyl-4-hydroxylated Chalcone Derivatives.
    Mathew B; Mathew GE; Uçar G; Baysal I; Suresh J; Mathew S; Haridas A; Jayaprakash V
    Chem Biodivers; 2016 Aug; 13(8):1046-52. PubMed ID: 27402375
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
    Park HR; Kim J; Kim T; Jo S; Yeom M; Moon B; Choo IH; Lee J; Lim EJ; Park KD; Min SJ; Nam G; Keum G; Lee CJ; Choo H
    Bioorg Med Chem; 2013 Sep; 21(17):5480-7. PubMed ID: 23810676
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potent, selective and reversible hMAO-B inhibition by benzalphthalides: Synthesis, enzymatic and cellular evaluations and virtual docking and predictive studies.
    Olmo ED; Barboza B; Delgado-Esteban M; Escala N; Jiménez-Blasco D; Lopez-Pérez JL; Cillero de la Fuente L; Quezada E; Munín J; Viña D; Bolaños JP; Feliciano AS
    Bioorg Chem; 2024 May; 146():107255. PubMed ID: 38457955
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chromone-deferiprone hybrids as novel MAO-B inhibitors and iron chelators for the treatment of Alzheimer's disease.
    Zou DJ; Liu RZ; Lv YJ; Guo JN; Fan ML; Zhang CJ; Xie YY
    Org Biomol Chem; 2024 Jul; 22(30):6189-6197. PubMed ID: 39027944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.
    Pisani L; Farina R; Catto M; Iacobazzi RM; Nicolotti O; Cellamare S; Mangiatordi GF; Denora N; Soto-Otero R; Siragusa L; Altomare CD; Carotti A
    J Med Chem; 2016 Jul; 59(14):6791-806. PubMed ID: 27347731
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monoamine oxidase inhibitory activity of methoxy-substituted chalcones.
    Mathew B; Mathew GE; Ucar G; Joy M; Nafna EK; Lohidakshan KK; Suresh J
    Int J Biol Macromol; 2017 Nov; 104(Pt A):1321-1329. PubMed ID: 28577983
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biological activity evaluation of novel monoamine oxidase inhibitory compounds targeting Parkinson disease.
    Dawbaa S; Evren AE; Sağlik BN; Gundogdu-Karaburun N; Karaburun AC
    Future Med Chem; 2022 Nov; 14(22):1663-1679. PubMed ID: 36317547
    [No Abstract]   [Full Text] [Related]  

  • 54. Selectivity of Dietary Phenolics for Inhibition of Human Monoamine Oxidases A and B.
    Zhang Z; Hamada H; Gerk PM
    Biomed Res Int; 2019; 2019():8361858. PubMed ID: 30809547
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Umbelliferone derivatives exert neuroprotective effects by inhibiting monoamine oxidase A, self-amyloidβ aggregation, and lipid peroxidation.
    Seong SH; Ali MY; Jung HA; Choi JS
    Bioorg Chem; 2019 Nov; 92():103293. PubMed ID: 31557622
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of monoamine oxidase by indole and benzofuran derivatives.
    Prins LH; Petzer JP; Malan SF
    Eur J Med Chem; 2010 Oct; 45(10):4458-66. PubMed ID: 20674099
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery of benzamide-hydroxypyridinone hybrids as potent multi-targeting agents for the treatment of Alzheimer's disease.
    Jiang X; Guo J; Zhang C; Gu J; Zhou T; Bai R; Xie Y
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2045-2054. PubMed ID: 34607518
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 3-Amidocoumarins as Potential Multifunctional Agents against Neurodegenerative Diseases.
    Matos MJ; Rodríguez-Enríquez F; Borges F; Santana L; Uriarte E; Estrada M; Rodríguez-Franco MI; Laguna R; Viña D
    ChemMedChem; 2015 Dec; 10(12):2071-9. PubMed ID: 26493007
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiparkinson potential of khellin on rotenone-induced Parkinson's disease in a zebrafish model: targeting MAO, inflammatory, and oxidative stress markers with molecular docking, MD simulations, and histopathology evidence.
    Hemanth Babu A; Prasanth DSNBK; Yaraguppi DA; Panda SP; Ahmad SF; Al-Mazroua HA; Sai AR; Praveen Kumar P
    Comp Biochem Physiol C Toxicol Pharmacol; 2024 Oct; 284():109997. PubMed ID: 39103133
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of Novel Phyto-chemicals from Ocimum basilicum for the Treatment of Parkinson's Disease using In Silico Approach.
    Mubashir N; Fatima R; Naeem S
    Curr Comput Aided Drug Des; 2020; 16(4):420-434. PubMed ID: 32883197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.